Antisense rallies ~18% in five days
Antisense Therapeutics Limited (ASX: ANP) has rallied in the past five days on no news.
ANP announced in September it had commenced dosing in the combination therapy trial of ATL1102 to treat Duchenne muscular dystrophy (DMD).
The company will be investigating the mouse model of DMD to assess the clinical utility of ATL1102 when used in combination with dystrophin restoration drugs (those that are approved in the US for the treatment of DMD).
“Antisense will hold its AGM next week and we should get a bit of an update on how that clinical trial is progressing,” Power said.
Power said ANP has a new chief commercial officer Dr Anthony Filippis to drive strategy.
The above from one of those news letters that HC wont let you name
ANP - Interesting general news items in BIO, page-124
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
